Keith Wycoff serves as Vice President of Research at Planet Biotechnology, Inc. since April 1995, where responsibilities include initiating and directing all research efforts aimed at developing antibody-based therapeutics. Additionally, Keith holds the position of Research Director at Life Science Angels since May 2010, leading the biotechnology investment committee. Keith is also a Board Member at Seal Rock Therapeutics, contributing to the development of a novel NASH therapeutic. Previous experience includes postdoctoral fellowships at UCLA, Noble Foundation, and Salk Institute for Biological Studies. Keith earned a PhD in Cellular and Developmental Biology from Harvard Kenneth C. Griffin Graduate School of Arts and Sciences and holds both a BS and MS in Botany from the University of California, Davis.